Management options for heart failure may include a combination of lifestyle changes, medications, implantable devices such as a pacemaker, PA pressure monitor or a defibrillator providing cardiac resynchronization therapy (CRT). Later stage advanced treatment options include a left ventricular assist device (LVAD) or transplant.
Women also experience differences in the epidemiology and pathophysiology that impact treatment of HFrEF and HFpEF.1 Factors such as lower body weight and plasma volume can contribute to a longer duration of action of lipophilic drugs and higher peak plasma concentrations of hydrophilic drugs. Similarly, lower cardiac output in women contributes to higher plasma levels of both hydrophilic and lipophilic drugs in women.2
May need lower doses of ACE inhibitors or ARBs than men, but insufficient representation in clinical trials makes this benefit unclear.
Sufficient representation of men in clinical trials shows clearer evidence base for improved outcomes and mortality.
Eligible women are less likely to have an ICD inserted making survival benefit data unclear. Women experience greater quality of life outcomes from CRT and improved hospitalization and mortality.
More likely to have an ICD inserted. Percutaneous mitral valve intervention is shown to have a greater impact on HF hospitalization.
Women are both less likely to receive MCS for a cardiogenic shock and more likely to experience complications on durable MCS support.
Men are more likely to receive both a durable LVAD or heart transplantation and experience lower mortality and better outcomes on LVAD support.
Experience greater concentric remodeling, load-induced diastolic dysfunction, arterial elastance and earlier wave reflection.
Experience greater injury response myocardial necrosis and adverse remodeling with aging.
Reduced cardiac output reserve with exercise can contribute to a greater rise in PCWP and poorer systemic and pulmonary artery compliance.
Experience adverse RV-PA coupling with reduced RV contractile reserve.
Benefit from ARNI due to relative natriuretic peptide deficit. Experience significant sex treatment with mineralocorticoid receptor antagonists.
Underlying ATTR pathology may limit neurohormonal blockage response.
MAT-2310090 v1.0
You are about to enter an Abbott country- or region-specific website.
Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions
Do you wish to continue and enter this website?
MAT-2305078 v1.0
